|
Italy-AS-AS Directorios de empresas
|
Noticias de la compañía :
- Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b . . .
Duvakitug is a potential best-in-class human IgG1-λ2 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A (TL1A), also known as TNF superfamily member 15 (TNFSF15)
- OP41 Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody . . .
Duvakitug is a human IgG1 monoclonal antibody that inhibits TL1A binding to DR3, a key driver of inflammation and fibrosis In comparison, it has less binding selectivity for DcR3, which regulates excess TL1A, maintaining homeostasis
- Duvakitug positive phase 2b results demonstrate best-in- class . . .
Duvakitug is currently under clinical investigation, and its efficacy and safety have not been evaluated by any regulatory authority
- Oral 66 – Duvakitug, an anti-TL1a mAb, Demonstrates Efficacy and . . .
Duvakitug is an anti-TL1A monoclonal antibody, a new therapeutic class being investigated for ulcerative colitis and Crohn’s disease The RELIEVE UCCD dose-range finding study was the first placebo-controlled trial of an anti-TL1A antibody in patients with Crohn’s disease
- Duvakitug delivers strong early results in very first anti . . . - Healio
Duvakitug achieved greater endoscopic response rates than placebo in moderate to severe Crohn’s disease Treatment was well tolerated, with no dose-related safety signals observed
- Novel Anti-TL1a Antibody Shows Potential for Crohn’s Disease
PHOENIX — Duvakitug, a novel anti-TL1a monoclonal antibody, demonstrated statistically significant differences in endoscopic response rates compared to placebo in adults with moderately to
- Teva, Sanofi score well with anti-TL1A drug in IBD test
Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD)
- S1450 Duvakitug, an Anti-TL1a mAb, Demonstrates Efficacy. . . : Official . . .
Conclusion: These are the first data reported for a double-blind, randomized, PBO-controlled induction study of an anti-TL1A antibody in patients with CD Duvakitug demonstrated statistically significant and clinically meaningful endoscopic response vs PBO with no emergent safety signals observed
- Teva and Sanofi Announce Accelerated Anti-TL1A Phase 2b Program for . . .
On October 3, 2023, Teva and Sanofi entered into an exclusive collaboration to co-develop and co-commercialize Teva’s duvakitug (anti-TL1A) for the treatment of UC and CD, two types of IBD
- Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated . . .
Duvakitug, a human monoclonal antibody targeting TL1A, is currently in phase 3 clinical studies for the treatment of UC and CD TL1A signaling is believed to amplify inflammation and drive fibrosis associated with IBD through binding to its receptor, DR3
|
|